Development of chemokine-cocktail therapy against hyman malignant gliomas using lymphocyte-specific chemokines
Development of chemokine-cocktail therapy against hyman malignant gliomas using lymphocyte-specific chemokines
批准号:
13671451
负责人:
TAKESHIMA Hideo
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002
中文摘要
淋巴细胞在人类恶性胶质瘤中经常被观察到,但其出现的机制尚不完全清楚。为了阐明恶性胶质瘤的肿瘤免疫,我们采用RT-PCR、Northern blot、免疫blot和免疫组化等方法分析了8种新型淋巴细胞特异性趋化因子在胶质瘤细胞系和胶质瘤组织中的表达,并考察了其与不同亚群淋巴细胞浸润的相关性。对于检测的8种趋化因子(LARC, TARC, ELC, SLC, PARC, LEC, HCC-2和SCM-1a),通过RT-PCR可以在所有12种胶质瘤细胞系中清楚地检测到LARC的表达。此外,在大多数胶质瘤细胞系中均可检测到TARC和SCM-1a的表达。然而,大多数趋化因子的表达水平较低,因此除了LARC在2个细胞系中表达外,Northern blot分析无法显示它们的表达。肉豆蔻酸佛酚酯可强烈诱导U87 MG细胞中LARC mRNA和LARC蛋白的表达。8个胶质母细胞瘤组织中有4个通过免疫印迹检测,33个样本中有9个(27.3%)通过免疫组织化学检测产生了LARC蛋白。有趣的是,LARC染色阳性与CD8-、CD4-和cd45r0阳性细胞的浸润显著相关(p<0.001)。虽然LARC的组成表达水平较低,但某些刺激可强烈诱导其表达,并在人恶性胶质瘤的肿瘤免疫中发挥重要作用。
英文摘要
Lymphocytes are frequently observed in human malignant glioma, the mechanism(s) underlying their appearance is not fully understood. To clarify tumor immunity in malignant gliomas, we analyzed the expression of 8 novel lymphocyte-specific chemokines in human glioma cell lines and glioma tissues by RT-PCR, Northern blot, immunoblot and immunohistochemistry, and examined the correlation with the infiltration of various subsets of lymphocytes. For the 8 chemokines examined (LARC, TARC, ELC, SLC, PARC, LEC, HCC-2, and SCM-1a), expression of LARC was clearly detectable in all 12 glioma cell lines by RT-PCR. Additionally, expression of TARC and SCM-1a was detectable in the majority of glioma cell lines. However, the expression level of most chemokines was low, so that Northern blot analysis could not demonstrate their expression with the exception of LARC in 2 cell lines. Expression of LARC mRNA and LARC protein was strongly induced by phorbol myristate ester in U87 MG cells. The production of LARC protein was demonstrated in 4 of 8 glioblastoma tissues by immunoblot, and 9 of 33 samples (27.3%) by immunohistochemistry. Interestingly, the positivist of LARC staining was significantly correlated with the infiltration of CD8-, CD4-, and CD45R0-positive cells (p<0.001).Although the constitutive expression level of LARC is low, certain stimulations could strongly induce its expression, and play a crucial role in the tumor immunity of human malignant glioma.
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Yamahata H, Takeshima H, et al.: "The role of thrombin in the neo-vascularization of malignant gliomas : An intrinsic modulator for the up-regulation of vascular endothelial growth factor"Int J Oncol. 20. 921-928 (2002)
Yamahata H、Takeshima H 等人:“凝血酶在恶性神经胶质瘤新生血管形成中的作用:血管内皮生长因子上调的内在调节剂”Int J Oncol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Miyanohara O, Takeshima H, et al.: "Diagnostic significance of soluble c-kit in the cerebrospinal fluid of patients with germ cell tumors"J Neurosurg. 97. 177-183 (2002)
Miyanohara O、Takeshima H 等:“生殖细胞肿瘤患者脑脊液中可溶性 c-kit 的诊断意义”J Neurosurg。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kino T, Takeshima H, et al.: "Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma"Genes Cells. 6. 441-454 (2001)
Kino T、Takeshima H 等人:“鉴定 NF2 基因启动子中的顺式作用区域作为神经鞘瘤中突变和甲基化依赖性沉默的潜在靶标”Genes Cells。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Obara S, Takeshima H, et al.: "Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK)"Cancer Lett. 185. 153-161 (2002)
Obara S、Takeshima H 等人:“西立伐他汀与粘着斑激酶 (FAK) 结合抑制人类胶质母细胞瘤细胞的迁移”Cancer Lett。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Tamura T, Takeshima H, et al.: "Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and rectal cancer"Hum Gene Ther. 12. 1265-1276 (2001)
Tamura T、Takeshima H 等人:“通过体内电穿孔进行白细胞介素 12 表达质粒的瘤内递送对于结肠癌和直肠癌有效”Hum Gene Ther。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 15 条
Identification of the novel molecular marker for oligodendroglial tumor using induced differentiation system against glioma stem cell.
-
批准号:20390387
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.56万
-
财政年份:2008
-
负责人:TAKESHIMA Hideo
-
依托单位:
Mechanisms underlying inhibition of tumor-immunology in malignant glioma and development of immune-activation therapy using suicide-chimeric molecule
-
批准号:17390405
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$10.5万
-
财政年份:2005
-
负责人:TAKESHIMA Hideo
-
依托单位:
Development of the clinical diagnosis and treatment of CNS germinoma using KIT as a target
-
批准号:15591536
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2003
-
负责人:TAKESHIMA Hideo
-
依托单位:
Role of NF2 tumor suppressor gene promoter in the tumorigenesis
-
批准号:11671371
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:1999
-
负责人:TAKESHIMA Hideo
-
依托单位:
Development of the Gene-missile therapy against human malignant gliomas using monocyte as a carrier.
-
批准号:09671431
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:TAKESHIMA Hideo
-
依托单位:
国内基金
海外基金
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位: